Julien Meyrat | 15 February 2016 |
Almost one tenth of European pharmaceutical R&D investments in 2014 took place in Belgium.
According to a study by website pharma.be, nearly one tenth of European pharmaceutical R&D investments in 2014 took place in Belgium (€2.3 billion which, considering the population, puts it second behind Denmark).
This makes the country one of the main poles of biopharmaceuticals in the Union, generating almost one sixth of European medicine exports. In particular, the Belgian sector boasts more than 200 pharmaceutical enterprises and over 34,000 employees in the sector.
The pharmaceutical industry furthermore signed a “future deal” with the federal government in 2015, aiming to consolidate its good position (ease of access to recent treatments, modernisation of procedures, etc.).
The study is available on line.
The Belgian biopharmaceutical sector in figures
- More than 200 pharmaceutical businesses
- 34,000 highly qualified employees
- A unique ecosystem of multinationals, biotech firms and specialised SMEs
- Close collaboration with universities and research centres
- €2.3 billion in R&D investments (2014)
- A pole of attraction for clinical trials: no. 1 in Europe and no. 2 on a global level*
- A unique geostrategic positioning: an asset for distribution in Europe
* Based on the number of clinical trials per inhabitant.
Source : Pharma figures 2014, Clinical trial.gov (September 2014) www.processpropre.fr
